We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$150M
AUM Growth
-$10.7M
(-6.6%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-7.61%
Top 10 Holdings %
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16
Avg Time Held
3.4
quarters
Top 10 Avg Time Held
2.2
quarters
Top 20 Avg Time Held
3.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$3.24M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$3.07M |
| 3 |
Ocular Therapeutix
OCUL
|
+$2.58M |
| 4 |
MacroGenics
MGNX
|
+$2.53M |
| 5 |
Neurogene
NGNE
|
+$2.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$5.29M |
| 2 |
Assertio
ASRT
|
+$4.53M |
| 3 |
Geron
GERN
|
+$3.87M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$3.38M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$2.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.89% |
| 2 | Miscellaneous | 8.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Nektar Therapeutics
NKTR
$1.29B
| – | – |
-3,333
| Closed | -$688K | – |
|
52
Prothena Corp
PRTA
$429M
| – | – |
-14,000
| Closed | -$576K | – |
|
|
53
DELISTED
Sage Therapeutics
SAGE
| – | – |
-165,000
| Closed | -$5.29M | – |
|
54
Travere Therapeutics
TVTX
$4.88B
| – | – |
-150,000
| Closed | -$2.05M | – |
|
55
DELISTED
Xoma
XOMA
| – | – |
-67,500
| Closed | -$1.04M | – |
|
56
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-25,000
| Closed | -$417K | – |
|
57
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| – | – |
-915
| Closed | -$1.18M | – |
|
|
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-80,000
| Closed | -$3.38M | – |
|
|
CHMA
59
DELISTED
Chiasma, Inc. Common Stock
CHMA
| – | – |
-20,000
| Closed | -$183K | – |
|
|
AKAO
60
DELISTED
Achaogen Inc
AKAO
| – | – |
-255,000
| Closed | -$704K | – |
|
|
MDVN
61
DELISTED
MEDIVATION, INC.
MDVN
| – | – |
-14,500
| Closed | -$667K | – |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q2 2016 Portfolio in Review
As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.
- Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
- Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
- Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
- Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
- Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
- Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
- Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.
Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.